Addition requirement for certain pharmaceutical marketing expenses

This bill requires pharmaceutical manufacturers in Minnesota to add back certain direct-to-consumer advertising expenses when calculating their state income and franchise taxes. It specifically targets marketing costs for prescription drugs and biologics that are directed at consumers through media channels like television, radio, print, and social media. The legislation does not change how these companies deduct these costs for federal tax purposes but instead prevents them from using those same deductions to lower their Minnesota tax liability. These changes will take effect for tax years beginning after December 31, 2026.